Grufity logoGrufity logo
ScreenerStocksFundsSectorsWatchlists
SILK

Silk Road Medical Inc

SILK

9.95USD+0.22 (+2.26%)Market Closed
Watchlist

Market Summary

USD9.95+0.22
Market Closed
2.26%

SILK Stock Price

View Fullscreen

SILK RSI Chart

SILK Valuation

Market Cap

387.1M

Price/Earnings (Trailing)

-6.99

Price/Sales (Trailing)

2.28

Price/Free Cashflow

-13.39

SILK Price/Sales (Trailing)

SILK Profitability

Return on Equity

-34.76%

Return on Assets

-21.11%

Free Cashflow Yield

-7.47%

SILK Fundamentals

SILK Revenue

Revenue (TTM)

169.9M

Revenue Y/Y

18.89%

Revenue Q/Q

-1.91%

SILK Earnings

Earnings (TTM)

-55.3M

Earnings Y/Y

-23.93%

Earnings Q/Q

5.16%

Price Action

Last 7 days

20.3%

Last 30 days

13.6%

Last 90 days

-47.2%

Trailing 12 Months

-81.7%

How does SILK drawdown profile look like?

SILK Financial Health

Current Ratio

11.03

SILK Investor Care

Shares Dilution (1Y)

9.97%

Diluted EPS (TTM)

-1.44

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023150.7M162.9M169.9M0
2022107.4M114.2M126.8M138.6M
202178.3M89.7M94.3M101.5M
202069.5M69.7M72.7M75.2M
201941.6M48.8M56.2M63.4M
201822.8M26.9M30.8M34.6M
201700014.3M

Latest Insider Trading transactions for SILK

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Nov 02, 2023
mckhann chas
acquired
-
-
612,083
chief executive officer
Oct 27, 2023
jones marie l.
sold
-4,334
6.607
-656
cao and vp, finance
Oct 04, 2023
buchanan lucas w.
sold
-40,523
15.223
-2,662
coo/cfo
Sep 15, 2023
klemz kevin m
acquired
-
-
86,076
evp/chief legal officer/sec.
Sep 15, 2023
davis andrew s.
acquired
-
-
121,519
chief commercial officer
Sep 15, 2023
buchanan lucas w.
acquired
-
-
222,785
coo/cfo
Sep 15, 2023
ruedy richard
acquired
-
-
28,354
evpclin&reg.affairs&qa
Sep 15, 2023
jones marie l.
acquired
-
-
7,595
cao and vp, finance
Aug 17, 2023
klemz kevin m
sold
-30,941
20.105
-1,539
evp/chief legal officer/sec.
Aug 03, 2023
davis andrew s.
sold
-145,797
22.134
-6,587
chief commercial officer

1–10 of 50

Which funds bought or sold SILK recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Nov 24, 2023
DEUTSCHE BANK AG\
reduced
-93.5
-10,639,600
328,806
-%
Nov 22, 2023
Graham Capital Management, L.P.
new
-
298,915
298,915
0.01%
Nov 21, 2023
Walleye Capital LLC
new
-
213,308
213,308
-%
Nov 21, 2023
COMERICA BANK
new
-
9,402
9,402
-%
Nov 17, 2023
TimesSquare Capital Management, LLC
sold off
-100
-12,259,000
-
-%
Nov 16, 2023
Financial Gravity Asset Management, Inc.
sold off
-100
-61.00
-
-%
Nov 15, 2023
JANE STREET GROUP, LLC
added
215
222,865
713,659
-%
Nov 15, 2023
Bullseye Asset Management LLC
added
39.82
-921,000
1,675,000
0.93%
Nov 15, 2023
Tudor Investment Corp Et Al
added
384
541,896
980,316
0.01%
Nov 15, 2023
iA Global Asset Management Inc.
sold off
-100
-1,974,000
-
-%

1–10 of 44

Latest Funds Activity

Are funds buying SILK calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own SILK
No. of Funds

Schedule 13G FIlings of Silk Road Medical Inc

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Oct 20, 2023
flynn james e
0.00%
0
SC 13G
Aug 10, 2023
alliancebernstein l.p.
0.1%
46,800
SC 13G/A
May 10, 2023
wasatch advisors lp
-
0
SC 13G/A
Feb 14, 2023
alliancebernstein l.p.
6.9%
2,616,795
SC 13G/A
Feb 13, 2023
capital world investors
7.8%
2,966,730
SC 13G/A
Feb 10, 2023
flynn james e
3.66%
1,396,640
SC 13G/A
Feb 09, 2023
vanguard group inc
9.34%
3,562,110
SC 13G/A
Feb 08, 2023
wasatch advisors inc
-
0
SC 13G/A
Jan 31, 2023
blackrock inc.
7.0%
2,664,762
SC 13G/A
Apr 11, 2022
alliancebernstein l.p.
10.7%
3,747,528
SC 13G/A

Recent SEC filings of Silk Road Medical Inc

View All Filings
Date Filed Form Type Document
Nov 08, 2023
10-Q
Quarterly Report
Nov 08, 2023
8-K
Current Report
Nov 06, 2023
144
Notice of Insider Sale Intent
Nov 03, 2023
3
Insider Trading
Nov 03, 2023
4
Insider Trading
Nov 02, 2023
8-K
Current Report
Oct 30, 2023
4
Insider Trading
Oct 20, 2023
SC 13G
Major Ownership Report
Oct 10, 2023
8-K
Current Report
Oct 06, 2023
4
Insider Trading

Peers (Alternatives to Silk Road Medical Inc)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
183.0B
40.0B
9.73% -2.70%
35.46
4.58
-11.26% -34.57%
71.3B
19.4B
-8.25% -5.16%
44.09
3.79
2.66% -16.58%
18.7B
15.0B
8.63% -30.19%
7.2
1.24
3.01% 209.09%
16.8B
3.8B
11.22% 10.68%
46.36
4.42
-1.48% -28.97%
MID-CAP
9.0B
12.7B
11.09% -16.77%
20.24
0.71
0.68% -30.25%
9.0B
2.7B
7.31% -26.28%
-56.42
3.3
-3.01% 97.36%
8.4B
3.4B
2.45% 18.85%
30.02
2.45
3.13% 18.17%
6.9B
3.9B
12.08% 3.35%
-31.81
1.76
-2.62% 73.28%
2.9B
342.6M
6.85% -17.46%
-245.59
8.59
42.19% 84.14%
2.5B
6.6B
-16.25% -11.02%
12.27
0.37
2.61% 0.62%
SMALL-CAP
1.2B
3.1B
8.50% -59.80%
-2.91
0.4
7.95% -550.16%
333.0M
163.3M
7.72% -27.92%
-13.55
2.04
7.14% -56.09%
271.9M
335.9M
-0.73% -44.59%
42.18
0.81
4.71% 116.39%
74.8M
50.3M
-17.56% 18.68%
-4.94
1.49
3.23% 20.81%
5.1M
3.8M
9.63% -51.71%
-0.44
1.34
17.30% 10.67%

Silk Road Medical Inc News

Latest updates
Knox Daily04 Dec 202303:24 pm16 hours ago
GlobeNewswire21 Nov 202311:14 pm13 days ago
InvestorsObserver13 Nov 202308:00 am21 days ago
Bluefield Daily Telegraph13 Nov 202308:00 am21 days ago
Yahoo Finance10 Nov 202308:00 am24 days ago
StreetInsider.com08 Nov 202309:19 pm26 days ago
Stockhouse Publishing05 Nov 202307:05 pm29 days ago
Simply Wall St03 Nov 202307:00 am32 days ago
Seeking Alpha03 Nov 202307:00 am32 days ago
GlobeNewswire31 Oct 202307:00 am35 days ago
Morningstar11 Oct 202307:00 am55 days ago
Nasdaq11 Oct 202307:00 am55 days ago
Investing.com UK11 Oct 202307:00 am55 days ago
Morningstar10 Oct 202307:00 am56 days ago

Financials for Silk Road Medical Inc

Income Statement (Last 12 Months)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue-1.9%44,435,00045,298,00040,131,00040,071,00037,374,00033,173,00028,021,00028,265,00024,701,00026,456,00022,053,00021,133,00020,067,00015,094,00018,933,00018,634,00017,026,00014,928,00012,766,00011,470,0009,614,000
Gross Profit0.3%32,385,00032,294,00027,605,00029,092,00028,066,00024,161,00019,444,00021,032,00018,625,00019,858,00016,515,00015,916,00014,579,0009,758,00013,683,00013,913,00012,856,00011,231,0009,427,0007,803,0006,732,000
Operating Expenses-1.2%46,056,00046,610,00044,515,00041,722,00037,292,00038,355,00035,398,00035,094,00031,916,00029,810,00026,678,00030,911,00023,913,00019,151,00022,823,00021,420,00020,251,00017,248,00016,573,00015,102,00011,415,000
  S&GA Expenses0.5%36,009,00035,830,00034,082,00032,522,00028,821,00027,700,00027,275,00027,595,00025,049,00022,549,00021,194,00020,872,00019,202,00015,758,00019,692,00018,156,00017,064,00014,135,00013,866,00011,712,0008,973,000
  R&D Expenses-6.8%10,047,00010,780,00010,433,0009,200,0008,471,00010,655,0008,123,0007,499,0006,867,0007,261,0005,484,00010,039,0004,711,0003,393,0003,131,0003,264,0003,187,0003,113,0002,707,0003,390,0002,442,000
EBITDA Margin-------0.41-0.44-0.47---0.55-0.56-0.64-0.67-0.67-0.74-0.57-0.66-0.78--
Interest Expenses1.2%1,732,0001,712,0001,693,0001,732,0001,714,0001,031,000621,000634,000633,000628,000623,000791,0001,215,0001,203,0001,202,0001,216,0001,176,0001,207,0001,352,0001,296,0001,065,000
EBT Margin-------0.44-0.46-0.49---0.60-0.63-0.72-0.75-0.75-0.83-0.67-0.77-0.90--
Net Income5.2%-12,788,000-13,484,000-16,460,000-12,614,000-10,319,000-15,398,000-16,679,000-14,693,000-13,885,000-10,539,000-10,694,000-16,756,000-10,315,000-10,353,000-9,941,000-8,291,000-8,007,000-11,959,000-24,158,000-15,618,000-8,953,000
Net Income Margin----0.36-0.40-0.45-0.53-0.52-0.49-0.55-0.54-0.61-0.63-0.53-0.53-0.55-0.83-----
Free Cashflow----12,434,000-4,291,000-5,115,000-11,383,000-16,797,000-14,184,000-7,627,000-9,843,000-12,039,000-14,524,000-4,531,000-11,926,000-11,929,000-5,459,000-----
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42017Q4
Assets-0.9%26126326027016316314315716616817017918418812713713914339.0043.0043.00
  Current Assets3.2%24123323025514714712814315415916417317818112011213213629.0039.0042.00
    Cash Equivalents2.8%29.0028.0050.0055.0051.0088.0094.0011010610295.0070.0063.0074.0028.0039.0011311916.0025.0034.00
  Inventory15.7%22.0019.0017.0019.0020.0018.0018.0018.0016.0013.0012.0010.0011.0012.0012.0010.009.009.008.006.003.00
  Net PPE-3.6%8.009.009.009.0010.0010.0010.008.005.003.003.003.003.003.003.003.003.003.003.003.000.00
Liabilities-0.1%10810810210610510375.0077.0077.0072.0069.0072.0064.0060.0063.0066.0061.0058.0091.0072.0036.00
  Current Liabilities-0.3%24.0024.0021.0024.0024.0021.0029.0026.0021.0017.0016.0020.0015.0012.0014.0017.0012.009.0011.0011.005.00
  Short Term Borrowings-------10.004.00-------------
    LT Debt, Non Current0.3%75.0075.0075.0075.0074.0074.0039.0045.0049.0049.0049.0049.0045.0045.0045.0045.0045.0045.0045.0044.0028.00
Shareholder's Equity-1.5%15315615816457.0060.0068.0079.0088.0096.0010110812012764.0072.0077.0084.00---
  Retained Earnings-3.4%-386-373-360-343-331-320-305-288-274-260-249-238-222-211-201-191-183-175-163-139-101
  Additional Paid-In Capital2.0%5405295185083883813733683623563513463423392652632612605.005.003.00
Shares Outstanding0.2%39.0039.0039.0038.0035.0035.0035.0035.0035.0035.0034.0034.0034.0032.0031.0023.0031.0028.00-1.001.00
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations-47.3%-6,798-4,616-12,147-2,724-4,726-10,406-14,725-11,432-6,495-9,036-11,972-14,269-4,423-11,581-11,795-5,261-6,346-9,383-8,620-5,390-6,367
  Share Based Compensation0.5%10,24710,1998,8387,5456,3396,1614,9783,9843,6863,4093,5332,2732,0061,6541,293954924837262226194
Cashflow From Investing138.9%7,456-19,1586,106-104,951-32,895-22,150-2,07214,2507,96814,19336,23312,898-7,386-14,797-108-69,619-131-89.00-117-102-1,164
Cashflow From Financing-91.8%1301,5921,110111,7271,21326,5911681,7712,2422,1178488,36983572,2682741,784507112,210-744-22615,218

SILK Income Statement

2023-09-30
Condensed Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Condensed Statements of Operations and Comprehensive Loss [Abstract]    
Revenue$ 44,435$ 37,374$ 129,864$ 98,567
Cost of goods sold12,0509,30837,58026,897
Gross profit32,38528,06692,28471,670
Operating expenses:    
Research and development10,0478,47131,26027,249
Selling, general and administrative36,00928,821105,92383,795
Total operating expenses46,05637,292137,183111,044
Loss from operations(13,671)(9,226)(44,899)(39,374)
Interest income2,6176177,339751
Interest expense(1,732)(1,714)(5,137)(3,366)
Loss on debt extinguishment   (245)
Other income (expense), net(2)4(35)(162)
Net loss(12,788)(10,319)(42,732)(42,396)
Other comprehensive loss:    
Unrealized gain (loss) on investments, net47(189)(118)(191)
Other comprehensive loss47(189)(118)(191)
Net loss and comprehensive loss$ (12,741)$ (10,508)$ (42,850)$ (42,587)
Net loss per share, basic$ (0.33)$ (0.29)$ (1.10)$ (1.21)
Net loss per share, diluted$ (0.33)$ (0.29)$ (1.10)$ (1.21)
Weighted average common shares used to compute net loss per share, basic38,865,01135,303,95838,722,01235,157,840
Weighted average common shares used to compute net loss per share, diluted38,865,01135,303,95838,722,01235,157,840

SILK Balance Sheet

2023-09-30
Condensed Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 29,188$ 55,358
Short-term investments163,673158,316
Accounts receivable, net21,77918,007
Inventories22,06619,293
Prepaid expenses and other current assets4,2773,924
Total current assets240,983254,898
Long-term investments4,348 
Property and equipment, net8,3379,372
Restricted cash0155
Other non-current assets7,1965,260
Total assets260,864269,685
Current liabilities:  
Accounts payable5,0942,523
Accrued liabilities18,92821,965
Total current liabilities24,02224,488
Long-term debt75,36474,596
Other liabilities8,3366,726
Total liabilities107,722105,810
Commitments and contingencies (Note 7)
Stockholders' equity:  
Preferred stock, $0.001 par value Shares authorized: 5,000,000 at September 30, 2023 and December 31, 2022 Shares issued and outstanding: none at September 30, 2023 and December 31, 2022
Common stock, $0.001 par value Shares authorized: 100,000,000 at September 30, 2023 and December 31, 2022 Shares issued and outstanding: 38,907,789 and 38,355,972 at September 30, 2023 and December 31, 2022, respectively3938
Additional paid-in capital539,831507,715
Accumulated other comprehensive loss(284)(166)
Accumulated deficit(386,444)(343,712)
Total stockholders’ equity153,142163,875
Total liabilities and stockholders’ equity$ 260,864$ 269,685
SILK
Silk Road Medical, Inc. operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization. Its products include ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and initiate temporary blood flow reversal; ENROUTE Transcarotid Stent System, a self-expanding, self-tapering stent; ENHANCE Transcarotid Peripheral Access Kit for use in gaining initial access to the common carotid artery; ENROUTE 0.014 Guidewire for navigating and crossing the target lesion for delivery of interventional devices; and ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter, a specialty balloon for the TCAR procedure. Silk Road Medical, Inc. was incorporated in 2007 and is headquartered in Sunnyvale, California.
 CEO
 WEBSITEsilkroadmed.com
 EMPLOYEES414

Silk Road Medical Inc Frequently Asked Questions


What is the ticker symbol for Silk Road Medical Inc? What does SILK stand for in stocks?

SILK is the stock ticker symbol of Silk Road Medical Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Silk Road Medical Inc (SILK)?

As of Mon Dec 04 2023, market cap of Silk Road Medical Inc is 387.13 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SILK stock?

You can check SILK's fair value in chart. The fair value of Silk Road Medical Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Silk Road Medical Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SILK so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Silk Road Medical Inc a good stock to buy?

The fair value guage provides a quick view whether SILK is over valued or under valued. Whether Silk Road Medical Inc is cheap or expensive depends on the assumptions which impact Silk Road Medical Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SILK.

What is Silk Road Medical Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Dec 04 2023, SILK's PE ratio (Price to Earnings) is -6.99 and Price to Sales (PS) ratio is 2.28. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SILK PE ratio will change depending on the future growth rate expectations of investors.